METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED SUBJECTS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 15, 2011
app pub date -
Jun 10, 2011
filing date -
Jun 11, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully